Stay updated on Efficacy & Safety of M2951 in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-30T18:09:29.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed information about a clinical trial for M2951 in relapsing multiple sclerosis and the addition of new drug information, specifically regarding Evobrutinib and Tecfidera. The collaborators for the study have been confirmed as Merck KGaA, Darmstadt, Germany.
    Difference
    19%
    Check dated 2025-04-16T13:15:02.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T06:41:46.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-04-01T22:50:07.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-24T20:41:03.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.8%
    Check dated 2025-02-10T09:41:02.000Z thumbnail image

Stay in the know with updates to Efficacy & Safety of M2951 in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy & Safety of M2951 in Relapsing MS Clinical Trial page.